Home › NDC Lookup › Ingredients › Naloxone Hydrochloride › 45802-0578-84
NALOXONE HYDROCHLORIDE 4 mg/.1mL Spray, 2 vials — NDC 45802-0578-84 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NALOXONE HYDROCHLORIDE 4 mg/.1mL Spray, 2 vials — NDC 45802-578-84 (Billing 45802-0578-84)

by Padagis Israel Pharmaceuticals Ltd · 2 VIAL, SINGLE-DOSE in 1 CARTON / .1 mL in 1 VIAL, SINGLE-DOSE

This is a package of 2 vials of NALOXONE HYDROCHLORIDE 4 mg/.1mL Spray from Padagis Israel Pharmaceuticals Ltd, marketed since Jul 2023 and currently FDA-listed; retail pharmacies pay about $17.18 per vial (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 45802-0578-84
🏷️ FDA NDC (as labeled) 45802-578-84 billing pads the product segment with a zero
This package
Contains2 vials Cost per ea$17.18 NADAC Per package$34.35 / 2 vials Pack sizes2 compare ↓
Also priced by: Medicaid pays $216.94/unit — full pricing hub ↓
Main listing for product 45802-578 · Also comes in: 24 vials 45802-578-24
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-578-84
Product NDC 45802-578
11-digit billing NDC 45802057884
NCPDP billing unit EA — each (per item)
RxCUI 1725059
UNII F850569PQR
Application # ANDA211951
SPL Set ID b5d40220-f194-4835-b70c-f304ecb222d5
Established class (EPC) Opioid Antagonist
Mechanism of action Opioid Antagonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-07-30
Route NASAL
Dosage form SPRAY
Substance NALOXONE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 93400020100920
GCN Seq No 075222
GCN 40233
HICL code 001874
Ingredient (HICL) Naloxone Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H3
Therapeutic class — intermediate (HIC2) Analgesics
HIC3 code H3T
Therapeutic class — specific (HIC3) Opioid Antagonists
AHFS code 28:10.00.00
AHFS class Opioid Antagonists (28:10)
FDB label name NALOXONE HCL 4 MG NASAL SPRAY
FDB brand name Naloxone Hcl
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 075222
  • GCN: 40233
  • GPI-14 (Medi-Span): 93400020100920
  • HICL (First Databank): 001874
  • AHFS class code: 28:10.00.00
  • RxCUI (RxNorm): 1725059
Why two NDCs? The FDA registers this code as 45802-578-84 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0578-84. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Opioid Antagonist class.

Pharmacologic class Opioid Antagonist
Drug family (ATC) Other opioids, Natural opium alkaloids, Benzomorphan derivatives
How it works Opioid Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NALOXONE HCL 4 MG NASAL SPRAY Ingredient Naloxone Hcl
📖 What it is MedlinePlus · NLM

Naloxone nasal spray is used along with emergency medical treatment to reverse the life-threatening effects of a known or suspected opiate (narcotic) overdose. Naloxone nasal spray is in a class of medications called opiate antagonists. It works by blocking the effects of opiates to relieve dangerous symptoms caused by high levels of opiates in the blood.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It is an emergency medicine that reverses an opioid overdose. Signs include very slow or stopped breathing and being unresponsive. Some injection forms have extra hospital or milit...
  • Follow the instructions that came with your product. Nasal sprays go into one nostril. Zimhi goes into the outer thigh. Call 911 right away. If the person does not wake up or slips...
  • Naloxone can wear off before the opioid does. Breathing problems can come back. Stay with the person until emergency help arrives.
  • Why do I still need to call 911 if they wake up?
📖 Read our full Naloxone guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Naloxone Hydrochloride — tap one for details:

1,4-butanediolModerate Gamma Butyrolactone (gbl)Moderate Gamma-hydroxybutyrate (ghb)Moderate
🌿 Every supplement checked against Naloxone Hydrochloride (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $17.177 $34.35 / 2 vials
Medicaid paysCMS SDUD · 12 mo $216.94 $433.88 / 2 vials
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Feb 2024 Apr 2026 Jun 2026 Sep 2026 $26.474 $15.225
▼ Down 35% over the last 8 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0578-84 You're viewing this Main listing 2 VIAL, SINGLE-DOSE in 1 CARTON / .1 mL in 1 VIAL, SINGLE-DOSE $17.18 / ea $34.35 2023-07-30 — Active
45802-0578-24 45802-578-24 24 VIAL, SINGLE-DOSE in 1 CARTON / .1 mL in 1 VIAL, SINGLE-DOSE — — 2025-08-01 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 2 vials — 2 vial, single-dose in 1 carton / .1 ml in 1 vial, single-dose.
How does this package differ from NDC 45802-0578-24?
Both are NALOXONE HYDROCHLORIDE 4 mg/.1mL Spray — the drug itself is identical. This page's package is the 2 vials one, while NDC 45802-0578-24 is the 24 vials package.
What NDC number is used to bill for this package of NALOXONE HYDROCHLORIDE 4 mg/.1mL Spray?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Narcan 4 mg/.1mL 69547-0627-02 Emergent 2 vials $16.449 — Availability likely save 4%
Naloxone Hydrochloride 4 mg/.1mL 00480-3478-68 Teva 1 vial $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mLthis 45802-0578-84 Padagis 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 46122-0812-71 AMERISOURCE 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 60219-2104-07 Amneal 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 68001-0645-45 BluePoint 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 69238-2104-07 Amneal 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 70677-1283-01 Strategic 2 vials $17.177 — Availability likely —
Naloxone Hydrochloride 4 mg/.1mL 00093-2165-68 Teva 1 vial $34.270 — Discontinued +100%
Narcan 4 mg/.1mL 69547-0353-02 Emergent 2 vials $59.869 — Discontinued +249%
Naloxone Hydrochloride 4 mg/.1mL 00363-2140-02 Walgreen 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 00591-3871-99 Actavis 1 vial — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 42291-0493-02 AvKARE 2 vials — — FDA listed —
Narcan 4 mg/.1mL 50090-2422-00 A-S 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 50090-5908-00 A-S 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 50090-6710-00 A-S 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 50090-6963-00 A-S 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 51316-0210-02 CVS 2 vials — — FDA listed —
Narcan Naloxone Hci 4 mg/.1mL 51662-1240-01 HF 1 ml — — FDA listed —
NALOXONE HCl 4 mg/.1mL 51662-1620-01 HF 1 ml — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 51662-1659-02 HF 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 67296-1928-02 Redpharm 1 vial — — Discontinued —
Narcan 4 mg/.1mL 71205-0528-02 Proficient 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 71205-0707-02 Proficient 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 72162-2376-02 Bryant 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 76420-0867-02 Asclemed 1 vial — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 80425-0409-01 Advanced 2 vials — — FDA listed —
Narcan 4 mg/.1mL 85766-0076-02 Sportpharm 2 vials — — FDA listed —
Naloxone Hydrochloride 4 mg/.1mL 85766-0228-02 Sportpharm 1 vial — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Jul 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesbenzalkonium chloride, edetate disodium, hydrochloric acid, sodium chloride, water

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS ISRAEL PHARMACEUTICALS LTD
FDA applicationANDA211951 (ANDA)
Labeler code45802
First marketedJul 2023
Product typeHuman Otc Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 26 words ▾

Uses • to “revive” someone during an overdose from many prescription pain medications or street drugs such as heroin • this medicine can save a life

⏱️ Dosage and Administration ~1 min read ▾

Directions EMERGENCY TREATMENT OF OPIOID OVERDOSE Important: • For use in the nose only • Do not test nasal spray device before use • 1 nasal spray device contains 1 dose of medicine • Each device sprays 1 time only Step 1: CHECK if you suspect an overdose: • CHECK for a suspected overdose : the person will not wake up or is very sleepy or not breathing well • yell “Wake up!” • shake the person gently • if the person is not awake, go to Step 2 Step 2: GIVE 1st dose in the nose • HOLD the nasal spray device with your thumb on the bottom of the plunger • INSERT the nozzle into either NOSTRIL • PRESS the plunger firmly to give the 1st dose • 1 nasal spray device contains 1 dose Step 3: CALL • CALL 911 immediately after giving the 1st dose Step 4: WATCH & GIVE • WAIT 2-3 minutes after the 1st dose to give the medicine time to work • if the person wakes up : Go to Step 5 • if the person does not wake up : • CONTINUE TO GIVE doses every 2-3 minutes until the person wakes up • it is safe to keep giving doses Step 5: STAY • STAY until ambulance arrives: even if the person wakes up • GIVE another dose if the person becomes very sleepy again • You may need to give all the doses in the pack For opioid emergencies, call 911 .

For questions on Naloxone HCl Nasal Spray 4 mg, call Padagis ® at 1-866-634-9120 or go to www.padagisnaloxone.com. Step 1 Step 2 Step 3 Step 4 Step 5

⚠️ Warnings 27 words ▾

Warning When using this product some people may experience symptoms when they wake up, such as shaking, sweating, nausea, or feeling angry. This is to be expected.

🧪 Active Ingredient 9 words ▾

Active Ingredient (in each spray) Naloxone hydrochloride 4 mg

🧪 Inactive Ingredients 11 words ▾

Inactive Ingredients benzalkonium chloride, edetate disodium, hydrochloric acid, sodium chloride, water

🎯 Purpose 6 words ▾

Purpose Emergency treatment of opioid overdose

📄 Package Label / Principal Display Panel 111 words ▾

Package/Label Principal Display Panel NDC 45802-578-84 Compare to NARCAN ® active ingredient Padagis Naloxone Naloxone HCl Nasal Spray 4 mg Emergency Treatment of Opioid Overdose Original Prescription Strength Easy to Use Can Save a Life Designed to Rapidly Reverse the Effects of a Life-Threatening Opioid Emergency 2 SINGLE-DOSE NASAL SPRAY DEVICES 0.003 FL OZ (0.1mL) EACH FOR USE IN NOSE ONLY DO NOT TEST NASAL SPRAY DEVICE BEFORE USE 1 NASAL SPRAY DEVICE CONTAINS 1 DOSE OF MEDICINE EACH DEVICE SPRAYS 1 TIME ONLY SAFE TO USE EVEN IF OPIOIDS ARE NOT PRESENT Distributed by Padagis ® Allegan, MI 49010 www.padagisnaloxone.com 64QJ8 RT C4 Product of USA 64Q00 RT QS5 carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
495.3K
Units reimbursed last 4 qtrs
115.6K
Gross reimbursed last 4 qtrs
$25.08M
Avg / prescription
$50.64
Avg / unit
$216.94
Latest quarter Q1 2026
103.6KRx
Medicaid pays / ea
$216.94
gross reimbursed
vs
NADAC / ea
$17.1773
acquisition cost
=
Spread
+$199.76
+1163% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
44% FFS 56% MCO
Fee-for-service · 215,483 Rx Managed care · 279,864 Rx
State Medicaid map
Alaska: 229 units · 31.2 per 100k residents AK Maine: 320 units · 22.9 per 100k residents ME Washington: 7,595 units · 97.2 per 100k residents WA Idaho: no data reported ID Montana: 132 units · 11.7 per 100k residents MT North Dakota: 47 units · 6.0 per 100k residents ND Minnesota: 496 units · 8.6 per 100k residents MN Wisconsin: no data reported WI Michigan: 5,055 units · 50.4 per 100k residents MI New York: 10,203 units · 52.1 per 100k residents NY Vermont: 128 units · 19.8 per 100k residents VT New Hampshire: 63 units · 4.5 per 100k residents NH Oregon: 2,265 units · 53.5 per 100k residents OR Nevada: 1,458 units · 45.6 per 100k residents NV Wyoming: no data reported WY South Dakota: 265 units · 28.8 per 100k residents SD Iowa: 439 units · 13.7 per 100k residents IA Illinois: 15,180 units · 121 per 100k residents IL Indiana: 2,027 units · 29.5 per 100k residents IN Ohio: 5,304 units · 45.0 per 100k residents OH Pennsylvania: 12,361 units · 95.4 per 100k residents PA New Jersey: 2,791 units · 30.0 per 100k residents NJ Massachusetts: 1,843 units · 26.3 per 100k residents MA California: 15,230 units · 39.1 per 100k residents CA Utah: 782 units · 22.9 per 100k residents UT Colorado: 1,931 units · 32.9 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 7,845 units · 173 per 100k residents KY West Virginia: 1,706 units · 96.4 per 100k residents WV Virginia: 2,210 units · 25.4 per 100k residents VA Maryland: 3,045 units · 49.3 per 100k residents MD Connecticut: 105 units · 2.9 per 100k residents CT Rhode Island: 497 units · 45.4 per 100k residents RI Arizona: 2,625 units · 35.3 per 100k residents AZ New Mexico: 1,675 units · 79.2 per 100k residents NM Kansas: 547 units · 18.6 per 100k residents KS Arkansas: 1,050 units · 34.2 per 100k residents AR Tennessee: 1,684 units · 23.6 per 100k residents TN North Carolina: 1,704 units · 15.7 per 100k residents NC South Carolina: 26 units · 0.5 per 100k residents SC Delaware: 293 units · 28.4 per 100k residents DE Oklahoma: 1,626 units · 40.1 per 100k residents OK Louisiana: 904 units · 19.8 per 100k residents LA Mississippi: 125 units · 4.3 per 100k residents MS Alabama: 115 units · 2.3 per 100k residents AL Georgia: 335 units · 3.0 per 100k residents GA D.C.: 347 units · 51.1 per 100k residents DC Hawaii: 191 units · 13.3 per 100k residents HI Texas: 637 units · 2.1 per 100k residents TX Florida: 190 units · 0.8 per 100k residents FL
Units reimbursed · per 100k residents
0.5173
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 173 /100k
2 Illinois 121 /100k
3 Washington 97.2 /100k
4 West Virginia 96.4 /100k
5 Pennsylvania 95.4 /100k
6 New Mexico 79.2 /100k
7 Oregon 53.5 /100k
8 New York 52.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
2 vials this page45802-0578-84 495,347 Rx · $25,084,115
24 vials45802-0578-24 No Medicaid data
Drug total (last 4 qtrs): 495,347 Rx · 115,628 units · $25,084,115 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 45802-0573-30 · Padagis 45802-0580-01 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.